Carcinoma, Renal

Oncology·MeSH: Breast Neoplasms

11 drugs in development·4 companies·0 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
Belzutifan	Merck & Co., Inc. (MRK)
Zanzalintinib	Merck & Co., Inc. (MRK)

Phase 1(9)

Drug	Company
dff332	Novartis AG (NVS)
dff332	NOVARTIS AG (NVSEF)
gen-011	GENOCEA BIOSCIENCES, INC. (GNCA)
nir178	NOVARTIS AG (NVSEF)
nir178	Novartis AG (NVS)
pdr001	Novartis AG (NVS)
pdr001	NOVARTIS AG (NVSEF)
rad001	NOVARTIS AG (NVSEF)
rad001	Novartis AG (NVS)

Full trial data, competitive analysis, and AI-powered pipeline tracking.